This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by SASSOLAS, G. Articles by CABRERA, P. Search for Related Content PubMed PubMed Citation Articles by SASSOLAS, G. Articles by CABRERA, P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

Effects of the Somatostatin Analog BIM 23014 on the Secretion of Growth Hormone, Thyrotropin, and Digestive Peptides in Normal Men

Centre de Médecine Nucléaire (G.S., Y.K., R.C., S.M., J.P.Cal., P.Cab.) 69003 Lyon, France
INSERM Unité 45 Hopital Edouard Herriot (J.A.C.) 69003 Lyon, France

Address requests for reprints to: Dr. G. Sassolas, Centre de Medecine Nucleaire, 59 boulevard Pinel, Lyon 69003, France.

BIM 23014 (BIM) is a long-acting octapeptide somatostatin analog. We studied the effects of this analog on the secretion of GH, TSH, and gastroenteropancreatic hormones [secretin, motilin, and pancreatic polypeptide (PP)] in normal men. In the first protocol three BIM doses (125, 250, and 500 µg) and vehicle were administered sc in random order at 2000 h to eight normal young men. Plasma GH concentrations decreased during the first part of the night only after the highest dose (P < 0.05). Plasma secretin levels did not change, while plasma motilin decreased after the 250- and 500-µg doses (P = 0.05 and P = 0.02, respectively), and plasma PP decreased after all three doses (P < 0.05, P < 0.01, and P < 0.01, respectively) during the first part of the night. In the second protocol, eight men received BIM, administered by constant sc infusion during the night in a dose of 2 mg/12 h, or vehicle, either alone or in association with a 10 ng/kg·min iv GHRH or vehicle infusion. Nocturnal GH secretion was suppressed by the BIM infusion (P < 0.001). GH secretion, stimulated by GHRH infusion (P < 0.001), was reduced by concomitant BIM infusion (P < 0.001) and was pulsatile during the combined infusions. BIM infusion suppressed the physiological nighttime rise in plasma TSH levels. Plasma motilin and PP levels were reduced by BIM, when administered either alone or in combination with GHRH.

We conclude that: 1) BIM is capable of reducing GH secretion when administered sc in a dose of 500 µg and of abolishing nocturnal GH secretion when constantly infused at a dose of 2 mg/12 h; 2) BIM, constantly infused, reduces the nocturnal rise in TSH secretion; and 3) motilin and PP secretion are more sensitive than that of GH to BIM, as they are reduced by a lower dose

Received April 29, 1989.

This article has been cited by other articles:

				B. Astruc, P. Marbach, H. Bouterfa, C. Denot, M. Safari, A. Vitaliti, and M. Sheppard Long-Acting Octreotide and Prolonged-Release Lanreotide Formulations Have Different Pharmacokinetic Profiles J. Clin. Pharmacol., July 1, 2005; 45(7): 836 - 844. [Abstract] [Full Text] [PDF]

				E. V. Dimaraki, C. A. Jaffe, R. Demott-Friberg, M. Russell-Aulet, C. Y. Bowers, P. Marbach, and A. L. Barkan Generation of growth hormone pulsatility in women: evidence against somatostatin withdrawal as pulse initiator Am J Physiol Endocrinol Metab, March 1, 2001; 280(3): E489 - E495. [Abstract] [Full Text] [PDF]

				J. M. Kuhn, S. Arlot, H. Lefebvre, P. Caron, C. Cortet-Rudelli, F. Archambaud, P. Chanson, A. Tabarin, M. Goth, J. Blumberg, et al. Evaluation of the Treatment of Thyrotropin-Secreting Pituitary Adenomas with a Slow Release Formulation of the Somatostatin Analog Lanreotide J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1487 - 1491. [Abstract] [Full Text]

				M. K. Hong, K. M. Kent, R. Mehran, G. S. Mintz, F. O. Tio, M. Foegh, S. C. Wong, S. S. Cathapermal, and M. B. Leon Continuous Subcutaneous Angiopeptin Treatment Significantly Reduces Neointimal Hyperplasia in a Porcine Coronary In-Stent Restenosis Model Circulation, January 21, 1997; 95(2): 449 - 454. [Abstract] [Full Text]

				P. Caron, I. Morange-Ramos, M. Cogne, and P. Jaquet Three Year Follow-Up of Acromegalic Patients Treated with Intramuscular Slow-Release Lanreotide J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 18 - 22. [Abstract] [Full Text] [PDF]

				H. G. Maheshwari, S. S. Pezzoli, A. Rahim, S. M. Shalet, M. O. Thorner, and G. Baumann Pulsatile growth hormone secretion persists in genetic growth hormone-releasing hormone resistance Am J Physiol Endocrinol Metab, April 1, 2002; 282(4): E943 - E951. [Abstract] [Full Text] [PDF]